This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Avita Medical Shareholders Approve 2026 Governance and Equity Plans

Tipranks - Tipranks - Fri Jun 5, 5:32AM CDT

Claim 55% Off TipRanks

Avita Medical ( (RCEL) ) has shared an announcement.

AVITA Medical, Inc. held its 2026 Annual Meeting of Stockholders by live webcast on June 3, 2026, with a quorum of shareholders participating. Investors re-elected all seven directors, ratified Grant Thornton LLP as independent auditor for 2026, and approved an increase in the annual cash fee pool for non-executive directors from US$750,000 to US$900,000.

Stockholders also endorsed multiple equity grants of restricted stock units and options to non-executive directors, including initial awards to Dr. Michael Tarnoff and Joseph Woody. They backed say-on-pay for named executive officers, set the frequency for future compensation votes, and authorized both a 10-year warrant package for Perceptive Credit Holdings V, LP and additional equity issuance capacity under ASX Listing Rule 7.1A, expanding the company’s financial and capital-raising flexibility.

The most recent analyst rating on (RCEL) stock is a Buy
with a $6.00 price target.
To see the full list of analyst forecasts on Avita Medical stock,
see the RCEL Stock Forecast page.

Spark’s Take on RCEL Stock

According to Spark, TipRanks’ AI Analyst, RCEL is a Neutral.

The score is held down primarily by weak financial quality—large ongoing losses, negative free cash flow, and negative equity—despite strong gross margins. Offsetting this, the latest earnings call showed improving operating discipline, sequential growth, and reaffirmed FY2026 guidance, while technicals and valuation remain neutral-to-weak due to limited momentum and continued unprofitability.

To see Spark’s full report on RCEL stock,
click here.

More about Avita Medical

AVITA Medical, Inc. operates in the medical technology sector, focusing on advanced wound care and skin regeneration therapies. The company serves global healthcare markets and is listed in both the U.S. and Australia, with a shareholder base that votes on governance matters across these jurisdictions.

Average Trading Volume: 229,935

Technical Sentiment Signal: Strong Sell

Current Market Cap: $129M

Find detailed analytics on RCEL stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Market data provided by Barchart. Exchange delay details and data provider terms here. Information may be delayed, is provided 'as is' and is solely for informational purposes, and not for trading, investment or advice.